F. Michael (Mike) Ball was appointed CEO of Alcon on February 1, 2016. He is a member of the Executive Committee of Novartis.
Mr. Ball previously served as CEO of Hospira from 2011 to 2015. At Hospira, a world leader in injectable pharmaceuticals and infusion devices, he successfully turned the company around and grew it by focusing on product and quality improvements, and expanding its global footprint. Prior to Hospira, Mr. Ball held a number of senior leadership positions at Allergan, beginning in 1995. He served as president from 2006 to 2011 after having led the strategy and execution of global commercial activities for a wide range of businesses, including eye care pharmaceuticals, over-the-counter products and surgical devices. Before joining Allergan, Mr. Ball held roles of increasing responsibility in marketing and sales at Syntex Corporation and Eli Lilly. He began his career in the healthcare industry in 1981.
Mr. Ball holds a Bachelor of Science and a Master of Business Administration from Queen’s University in Canada.